A Multi-Center, Open-Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-Sponsored Phase 1 Cancer Studies
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2017
Price : $35 *
At a glance
- Drugs RG 7112 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Tumours
- Focus Adverse reactions
- Sponsors Roche
- 05 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
- 21 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.